Vol. 20/No. 8

Implementation of new standards for handling hazardous drugs in healthcare facilities is coming closer to reality now that the calendar has flipped to 2019.

Courtney D. DiNardo, MD, MSCE, discusses the findings of the phase I dose-escalating study that led to the initial approval of ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.

During an OncLive Peer Exchange® discussion, moderator Mark A. Socinski, MD, and other lung cancer experts from across the United States discuss what, in this context, the PACIFIC trial results mean for practicing oncologists and their patients.

Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia, part of a menu of targeted treatment options that is expanding as investigators learn more about the molecular heterogeneity of the disease.

Investigators at Cleveland Clinic have demonstrated that the direct oral anticoagulant rivaroxaban significantly reduces venous thromboembolism (VTE) and VTE-related death for patients with high-risk cancers treated in the outpatient setting.

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer.

Convincing data have made the case for the use of immunotherapy in the frontline for advanced renal cell carcinoma, ushering in a second revolution in slightly more than a decade.

Cancer cells that manipulate the DNA damage response to foster the genomic instability that underlies many of their hallmark processes become heavily reliant on intact pathways for their survival, creating a targetable Achilles heel that can be exploited therapeutically.

The optimal anticoagulant takes into consideration a variety of components, including patient preference, the indication for anticoagulation, comorbidities, reversibility, and other factors relevant to the clinical scenario.

The recent technological advances in medicine and related fields have encouraged a belief among many that there is little technology will not be able to accomplish in improving cancer-related clinical outcomes, but it must be acknowledged that clinical medicine and cancer biology are extremely complex arenas.